ERT in Pompe Disease: Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity

Towards an Individually Tailored Enzyme Replacement Therapy in Pompe Disease: A Controlled Study for Elucidation of Molecular Structures Contributing to Enzyme Uptake and Immunoreactivity

In the first part of this study, the aim is to characterize the molecular structure of wildtype GAA and, in particular, of mutated GAA variants with and without HSAT, in order to learn how mutation impairs uptake of GAA into the cell via the M6P receptor. In the second part of the study the aim is to learn to which epitopes antibodies bind and to which not. To accomplish this the investigators will synthesize and chemically modify the epitope peptides, in order to block effectively antibodies directed against the therapeutic enzyme.

Study Overview

• Status: Recruiting
• Conditions: Pompe-Disease

Detailed Description

Enzyme replacement therapy (ERT) with recombinant human GAA (rhGAA = alglucosidase alfa) is available since 2006, and has been shown effective in IOPD and LOPD; however the treatment response is variable and imperfect. This has prompted the development of a next-generation rhGAA with increased glycosylation and improved muscle cell uptake (avalglucosidase alfa). The efficacy of ERT significantly depends on the glycosylation status of the enzyme determining muscle cell uptake via the mannose-6-phosphate (M6P) receptor, and on the formation of antibodies directed against the recombinant enzyme. The impact of immunological factors on efficacy is highlighted by the occurrence of high sustained antibody titers (HSAT) in IOPD patients producing no GAA at all (CRIM-negative), that result in a worse outcome similar to that of untreated patients, if no immunomodulating medication is given. Such HSAT can also occur in IOPD patients synthesizing a non-functional GAA (CRIM-positive) and in some late onset Pompe Disease (LOPD) patients.

In the first part of this study, the investigators aim to characterize the molecular structure of wildtype GAA and, in particular, of mutated GAA variants with and without HSAT, in order to learn how mutation impairs uptake of GAA into the cell via the M6P receptor. To accomplish this, 5 healthy subjects and 45 Pompe disease patients will be studied (15 IOPD and 30 LOPD). The investigators will identify antibody epitopes in the sera of patients with rhGAA antibodies and determine and compare quantitatively their binding affinities, by using a combination of proteolytic affinity-mass spectrometry and surface plasmon resonance biosensor analysis. The investigators reason that specific mutations may affect the epitope status differently. Related to this, the investigators also speculate that glycosylations and M6P residues could modify epitopes in their close vicinity. These results will help to understand where the antibody binding epitopes are located.

In the second part of the study the investigators aim to learn to which epitopes antibodies bind and to which not. To accomplish this the epitope peptides will be synthesized and chemically modified, in order to block effectively antibodies directed against the therapeutic enzyme. Applying high affinity GAA epitope peptides capable of binding neutralizing antibodies is expected to potentially improve efficacy and safety of ERT, thereby providing a new targeted and personalized immunotolerance approach.

• Study Type: Observational
• Enrollment (Anticipated): 50

Contacts and Locations

• Study Contact: Name: Michael Przybylski, PhD; Phone Number: +49 6142 8345511; Email: michael.przybylski@stw.de
• Study Contact Backup: Name: Andreas Hahn, MD; Phone Number: +49 641 98543481; Email: andreas.hahn@paediat.med.uni-giessen.de

Study Locations

• Germany
  • Hessen
    • Rüsselsheim, Hessen, Germany, 65428
      • Recruiting
      • Centre for Analytical Biochemistry
      • Contact: Michael Przybylski, PhD; Phone Number: +49 6142 8345511; Email: michael.przybylski@stw.de
      • Contact: Loredana Lupu, PhD; Phone Number: +49 6142 8345512; Email: loredanalupu92@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

50 patients who meet all eligibility criteria will be enrolled in the study.

Description

Inclusion Criteria:

• All patients or their legal guardian and healthy volunteers with normal GAA enzyme activity and genotype will give informed consent to participate in this explorative, cross-sectional study.
• IOPD/LOPD patients will have a confirmed diagnosis of Pompe disease based on enzyme activity reduction and genetic GAA mutations.
• Both CRIM-positive and CRIM-negative IOPD patients will be included.
• Patients with IOPD/LOPD will be on enzyme replacement therapy on their individual treatment regime.
• Healthy volunteers will be included as controls for wildtype GAA analysis.

Exclusion Criteria:

• Patient/healthy volunteer or legal guardian do not agree to give informed consent.
• The patient/healthy volunteer is not capable to adhere to the study protocol.
• The patient is not treated with enzyme replacement therapy.

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Control
• Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of epitope numbers of acid-alpha-glucosidase (wtGAA; rhGAA; mutated GAA) antibodies	Epitope numbers of wtGAA, rhGAA, and mutated GAAs will determine the number of Pompe patients with polyclonal and monoclonal antibodies, and determine whether specific antibodies are more prevalent than others among Pompe patients.	Only at baseline visit
Determination of epitope locations of acid-alpha-glucosidase (wtGAA; rhGAA; mutated GAA) antibodies	Epitope locations of wtGAA, rhGAA, and mutated GAAs will determine the number of Pompe patients with polyclonal and monoclonal antibodies, and determine whether specific antibody epitopes are more prevalent than others among Pompe patients.	Only at baseline visit
Determination of epitope- specific affinities of acid-alpha-glucosidase (wtGAA; rhGAA; mutated GAA) antibodies	Epitope- specific affinities of acid-alpha-glucosidase (wtGAA; rhGAA; mutated GAA) antibodies in PD patients will be determined for correlation with mutations in GAA structure	Only at baseline visit

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Determination of the number of PD patients with specific neutralizing antibody epitopes	Neutralizing antibodies in PD patients may be differentiated by their epitope specificities.	Only at baseline visit
Determination of antibody titers in PD patients	Determination of epitope-specific antibody titers	Only at baseline visit

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Identification of the feasibility of epitope peptides for molecular apheresis of antibodies.	Quantitative determination of binding capacity of identified epitope peptides of PD patients to enable molecular apheresis of antibodies. To compare the antibody/epitope data obtained in this study with IARs and GAA antibody classes determined in the Sanofi-Genzyme lab.	Only at baseline visit

Collaborators and Investigators

• Sponsor: Centre for Analytical Biochemistry and Biomedical Mass Spectrometry
• Collaborators: University of Giessen
• Investigators: Principal Investigator: Michael Przybylski, PhD, Centre for Analytical Biochemistry, 65428 Ruesselsheim am Main, Germany

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2023
• Primary Completion (Anticipated): August 6, 2024
• Study Completion (Anticipated): October 7, 2024

Study Registration Dates

• First Submitted: June 29, 2022
• First Submitted That Met QC Criteria: July 2, 2022
• First Posted (Actual): July 7, 2022

Study Record Updates

• Last Update Posted (Estimate): February 20, 2023
• Last Update Submitted That Met QC Criteria: February 16, 2023
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Antibodies
• Additional Relevant MeSH Terms: Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Genetic Diseases, Inborn; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Lysosomal Storage Diseases, Nervous System; Glycogen Storage Disease; Glycogen Storage Disease Type II
• Other Study ID Numbers: SGZ-2020-13329

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes